N@N

CDEX Inc.: CDEX, Inc. Attends World Technology Network Awards as a Nominee

_{//science-technology.news-articles.net/content/2 .. orld-technology-network-awards-as-a-nominee.html}
^{Published in Science and Technology on Friday, July 24th 2009 at 6:10 GMT, Last Modified on 2009-07-24 06:10:26 by Market Wire}  

TUCSON, AZ--(Marketwire - July 24, 2009) - CDEX Inc. (OTCBB: [ CEXI ]) ([ www.cdex-inc.com ]) announces that on July 16, 2009, Greg Firmbach, CDEX Senior Vice President, represented CDEX at the World Technology Network Summit and Awards. The World Technology Awards are presented each year to the outstanding innovators from each sector within the technology arena (see [ http://www.wtn.net/summit2009 ]). CDEX, Inc. was honored to be among an internationally renowned group of nominees from all parts of the globe. CDEX was nominated for the Award in Health & Medicine, won by the Mayo Clinic. Other winners in their categories included Amazon.com, Facebook, YouTube, Honda Motors and The Phoenix Mars Landed Team.

CDEX's nomination was based on its life-saving ValiMed Medication Validation System which is now being deployed throughout major North American hospitals. ValiMed provides real-time validation of sterile compounded admixtures in today's fast-paced hospital pharmacy. ValiMed is unique in its ability to provide validation of "The Right Drug at The Right Dose" in seconds before the medication is released to a patient.

"We are pleased that ValiMed is being recognized for its life-saving properties as a leading innovation in the healthcare sector," said Mr. Firmbach. "We were honored to be considered alongside giants in technology innovation and I was proud to represent CDEX and discuss our technology with inventors and scientist from the United States, the Georgian Republic, Germany, France and even the President of Rwanda."

About CDEX

CDEX develops, manufactures and globally distributes products to the healthcare and security markets. The ValiMed™ product line provides life-saving validation of high-risk medications and returned narcotics. The ID2 ™ product line detects trace amounts of illegal drugs, such as methamphetamine. CDEX expects to advance its patented technologies to serve additional markets. To meet its plans, CDEX must strengthen its financial position as stated periodically in its SEC filings.

Non-historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as "expects," "plans, " "may," "believes," "should," "intends," and similar words. These statements pose risks and uncertainties that cannot be accurately predicted or quantified and, consequently, actual results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the protection of intellectual property and proprietary information, and other risks detailed periodically in filings with the SEC. There is no obligation to update any forward-looking statements.